Pharsight

1. List of Bijuva drug patents

Application	Filing Date	Opposition Party	Legal Status
EP19163006A	2022-09-22	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP19163006A	2022-09-21	Rieck, Markus	Granted and Under Opposition
EP12850845A	2022-03-09	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP12850845A	2022-03-09	Rieck, Markus	Granted and Under Opposition
EP12850845A	2022-03-09	Generics [UK] Limited	Granted and Under Opposition
EP13807188A	2022-01-14	Rieck, Markus	Revoked
EP13807121A	2019-12-23	Rieck, Markus	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8987237	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US10639375	THERAPEUTICSMD INC	Progesterone formulations	Nov, 2032 (9 years from now)
US11110099	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8993548	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US11103516	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US10206932	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8846649	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8846648	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US9114146	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US9114145	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US10675288	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US9301920	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US11033626	THERAPEUTICSMD INC	Progesterone formulations having a desirable pk profile	Nov, 2032 (9 years from now)
US9006222	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US10806740	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US11103513	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8933059	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US11166963	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US8633178	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)
US10052386	THERAPEUTICSMD INC	Progesterone formulations	Nov, 2032 (9 years from now)
US8993549	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)

Market Authorisation Date: 28 October, 2018

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/100 mg	06 Jan, 2020	1	16 May, 2022	21 Nov, 2032	Eligible

Strength	Dosage	Availability
0.5MG;100MG	CAPSULE;ORAL	Prescription
1MG;100MG	CAPSULE;ORAL	Prescription

BIJUVA family patents

United States

Australia

Japan

European Union

Korea, Republic of

Canada

Mexico

Russia

Brazil

Argentina

Israel

Spain

Croatia

Hungary

Poland

Portugal

South Africa

Lithuania

2. List of Bijuva drug patents

Application	Filing Date	Opposition Party	Legal Status
EP19163006A	2022-09-22	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP19163006A	2022-09-21	Rieck, Markus	Granted and Under Opposition
EP12850845A	2022-03-09	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP12850845A	2022-03-09	Rieck, Markus	Granted and Under Opposition
EP12850845A	2022-03-09	Generics [UK] Limited	Granted and Under Opposition
EP13807188A	2022-01-14	Rieck, Markus	Revoked
EP13807121A	2019-12-23	Rieck, Markus	Revoked

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529360	MAYNE PHARMA	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)